CTIS2022-502481-24-00招募中1 期
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Participants with Chronic Rhinosinusitis Without Nasal Polyps – The BiRCh Study - The BiRCh Study
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Insmed Inc.
- 入组人数
- 270
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Key Inclusion Criteria: • Male or female =18 years old and =75 years old • At least a 12-week history of CRSsNP • Ongoing symptoms of nasal congestion • Blood eosinophil count of =750 cells/µL at Screening • Previous sinonasal surgery for CRS and/or treatment with SCS or antibiotics for CRS within a year of Screening Visit • Received a stable daily dose regimen of MFNS for at least 4 weeks before randomization
排除标准
- •Key Exclusion Criteria: • Diagnosis of unilateral or bilateral chronic rhinosinusitis with nasal polyps • Participants who have certain conditions or are receiving certain treatments that could adversely affect the participant’s participation in the study, put the participant at unreasonable risk by participating in the study, or interfere with assessment of the effect of treatment
研究者
相似试验
进行中（未招募）
不适用
Phase IIB Psoriatic Arthritis Dose Ranging Study for BMS-945429 insubjects who are not responding to NSAIDs or non-biologic DMARDtherapyArthritis, PsoriaticMedDRA version: 14.1Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2011-004016-29-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO224
进行中（未招募）
不适用
Phase IIB Psoriatic Arthritis Dose Ranging Study for BMS-945429 in subjects who are not responding to NSAIDs or non-biologic DMARD therapyEUCTR2011-004016-29-DEBristol-Myers Squibb International Corporation224
进行中（未招募）
1 期
A study to learn how well the drug EDP 938 works and how safe it is in people who are able to walk around and are infected with Respiratory Syncytial VirusEUCTR2020-001529-30-BGEnanta Pharmaceuticals, Inc.70
进行中（未招募）
1 期
A study to learn how well the drug EDP 938-102 works and how safe it is in people who have had a bone marrow transplant and are infected with Respiratory Syncytial VirusRespiratory syncytial virus (RSV)MedDRA version: 21.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-002213-18-FREnanta Pharmaceuticals, Inc.200
进行中（未招募）
1 期
A Phase 2 clinical trial investigating the anti-virus effects, kinetics and safety of GS-5806 in adults with RSV (Respiratory Syncytial Virus) infection.Respiratory Syncytial Virus (RSV) Infection of the upper respiratory tract.MedDRA version: 19.0Level: LLTClassification code 10039247Term: RSV infectionSystem Organ Class: 100000004862EUCTR2014-002474-36-DEGilead Sciences, Inc.200